RT Journal Article SR Electronic T1 Sex Differences in Cardiovascular Impact of Early Metabolic Impairment: Interplay between Dysbiosis and Adipose Inflammation JF Molecular Pharmacology JO Mol Pharmacol FD American Society for Pharmacology and Experimental Therapeutics SP MOLPHARM-MR-2021-000338 DO 10.1124/molpharm.121.000338 A1 Haneen S Dwaib A1 Ibrahim AlZaim A1 Ghina Ajouz A1 Ali H. Eid A1 Ahmed F El-Yazbi YR 2021 UL http://molpharm.aspetjournals.org/content/early/2021/11/03/molpharm.121.000338.abstract AB The Evolving view of gut microbiota has shifted towards describing the colonic flora as a dynamic organ in continuous interaction with systemic physiological processes. Alterations of the normal gut bacterial profile, known as dysbiosis, has been linked to a wide array of pathologies. Of particular interest is the cardiovascular-metabolic disease continuum originating from positive energy intake and high fat diets. Accumulating evidence suggests a role for sex hormones in modulating the gut microbiome community. Such a role provides an additional layer of modulation of the early inflammatory changes culminating in negative metabolic and cardiovascular outcomes. In this review, we will shed the light on the role of sex hormones in cardiovascular dysfunction mediated by high fat diet-induced dysbiosis, together with the possible involvement of insulin resistance and adipose tissue inflammation. Insights into novel therapeutic interventions will be discussed as well. Significance Statement Increasing evidence implicates a role for dysbiosis in the cardiovascular complications of metabolic dysfunction. In this minireview, we summarize the available data on the sex-based differences in gut microbiota alterations associated with dietary patterns leading to metabolic impairment. We propose a role for a differential impact of adipose tissue inflammation across sexes in mediating the cardiovascular detrimental phenotype following diet-induced dysbiosis. Better understanding of this pathway will help introduce early approaches to mitigate cardiovascular deterioration in metabolic disease.